The pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) sued California state officials in federal court on December 8, 2017, over California’s new drug pricing law, which the group states is “unprecedented and unconstitutional.”
The pharmaceutical industry trade and lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) sued California state officials in federal court on December 8, 2017, over California’s new drug pricing law, Senate Bill 17 (SB 17), which the group states is “unprecedented and unconstitutional.” PhRMA argues that the California law, set to take effect January 1, 2019, “intentionally exports California’s policy choices regarding prescription drug pricing on the entire nation.”
The law, which was signed by Democratic Governor Jerry Brown on October 9, 2017, requires drug makers to provide 60 days’ notice of price increases above 16% when combined with increases from the previous 2 years, and they must also justify those increases. In addition, insurers will have to provide information about how drug costs affect premiums.
The bill would also require the California Office of Statewide Health Planning and Development (OSHPD) to enforce the provisions requiring manufacturer reporting, and would subject a manufacturer to liability for a civil penalty if the information described above is not reported. Some of the pricing information will be available to the public on OSHPD’s website. “Californians have the right to know why their medication costs are out of control, especially when pharmaceutical profits are soaring,” Governor Brown said in a statement.
In its complaint, PhRMA argues that SB 17 “forces drug manufacturers to publicly convey and implicitly endorse the state’s position that the manufacturers are to blame for the allegedly inflated prices of prescription drugs.” Further, the group says the law incorrectly and unfairly singles out drug makers for public condemnation, and will cause market disruptions such as drug stockpiling and reduced competition. The group seeks a court declaration that the law violates the First Amendment, the Fourteenth Amendment, and the Commerce Clause.
The bill’s sponsor, State Senator Ed Hernandez, said he was confident the law would be upheld, and said the lawsuit was another example of pharma refusing to accept any responsibility for the skyrocketing costs of prescription drugs.
Analysts have noted that PhRMA is concerned that the California law has been signed because California is such a large state, and could potentially serve as a model for other states seeking to act on drug prices. Maryland and Nevada are also implementing their own drug pricing legislation. PhRMA spent nearly $17 million in the last several years to oppose SB 17 before it was signed into law.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.